The long-term strategy for AI in drug discovery is a two-step process. First, create an AI platform to design effective drugs. Second, after a dozen or so AI-designed drugs succeed, use that data to convince regulators to trust AI predictions, potentially allowing future drugs to skip steps like animal testing and accelerate trials.

The endgame for CZI's work is hyper-personalized, "N of one" medicine. Instead of the current empirical approach (e.g., trying different antidepressants for months), AI models will simulate an individual's unique biology to predict which specific therapy will work, eliminating guesswork and patient suffering.

Health can be managed like a technology stack, with offensive layers (nutrition, exercise) and defensive layers (medicines for lipids, blood pressure). This proactive, systematic approach uses data to extend both lifespan and healthspan by addressing key risk areas.

The convergence of AI, massive health datasets, and genomics is creating a new paradigm in medicine. Instead of lengthy human trials, AI will prove drug solutions and create personalized therapeutics by analyzing an individual's condition against millions of data points, dramatically accelerating medical breakthroughs.

Current healthcare is a 'sick care' system that reacts to problems after they arise. AI health agents, by continuously integrating data from wearables, environment, and even smart appliances, can identify baseline health and prompt proactive behaviors to optimize wellness and prevent disease from occurring.

As AI enables early disease prediction (like Grail's cancer test), the number of sick patients will decrease. This erodes the traditional drug sales model, forcing pharma companies to create new revenue streams by monetizing predictive data and insights.

The traditional approach to cardiovascular disease is treating patients only after symptoms appear, by which point damage has occurred. Coursera Health's model is to intervene *before* biomarkers elevate, using early prediction and prevention to stop the cumulative damage that causes the disease, representing a fundamental paradigm shift in medicine.

For RNAi and antisense therapies targeting chronic conditions like cardiovascular disease, the critical competitive advantage is durability, not just efficacy. The ability to offer infrequent dosing, such as twice-yearly injections, represents a significant step-change from daily medications and is the key factor expected to drive market adoption.

Coursera Health's approach wasn't feasible a decade ago. Its existence depends on the recent convergence of three critical technologies: advanced AI for predictive modeling, mature RNAi therapeutics for safe and durable intervention, and large-scale longitudinal datasets like the UK Biobank to train the predictive models accurately.